Form 4: Aptevo Therapeutics Inc. Executive Exercises Stock Options

Sentiment:

SEC Form 4 Filing


SoYoung Kwon, SVP, GC, BD & Corp Affairs of Aptevo Therapeutics Inc., reports the exercise of stock options and subsequent disposal of shares.

Summary

  • On August 8, 2024, SoYoung Kwon, SVP, GC, BD & Corp Affairs of Aptevo Therapeutics Inc., exercised stock options, converting Restricted Stock Units (RSUs) into common stock.
  • The transaction involved the conversion of 213 RSUs into common stock.
  • Following the transaction, Kwon disposed of 801 shares.
  • The RSUs were granted on August 9, 2022, and vested in two approximately equal annual installments beginning on August 8, 2023.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, indicating a neutral sentiment. It reflects standard executive compensation practices.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment with shareholder interests.

Stakeholder Impact

  • The transaction provides transparency to shareholders regarding executive compensation and stock ownership.

Key Dates

DateDescription
08/09/2022Reporting person was granted 18,750 (426 post-split) RSUs, vesting in two approximately equal annual installments beginning on August 8, 2023.
08/08/2023First vesting date of RSUs.
08/08/2024Transaction date: Exercise of stock options and disposal of shares.
08/09/2024Date of Form 4 filing.

Keywords

Form 4, Aptevo Therapeutics Inc., Stock Options, RSU, SoYoung Kwon, Executive Compensation, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.